325 related articles for article (PubMed ID: 16816556)
21. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection.
Breen RA; Smith CJ; Bettinson H; Dart S; Bannister B; Johnson MA; Lipman MC
Thorax; 2004 Aug; 59(8):704-7. PubMed ID: 15282393
[TBL] [Abstract][Full Text] [Related]
23. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
[TBL] [Abstract][Full Text] [Related]
24. Tuberculosis epidemics driven by HIV: is prevention better than cure?
Currie CS; Williams BG; Cheng RC; Dye C
AIDS; 2003 Nov; 17(17):2501-8. PubMed ID: 14600522
[TBL] [Abstract][Full Text] [Related]
25. Incidence of tuberculosis in people living with the human immunodeficiency virus in Saudi Arabia.
Omair MA; Al-Ghamdi AA; Alrajhi AA
Int J Tuberc Lung Dis; 2010 May; 14(5):600-3. PubMed ID: 20392353
[TBL] [Abstract][Full Text] [Related]
26. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART.
Muga R; Ferreros I; Langohr K; de Olalla PG; Del Romero J; Quintana M; Alastrue I; Belda J; Tor J; Pérez-Hoyos S; Del Amo J;
AIDS; 2007 Nov; 21(18):2521-7. PubMed ID: 18025889
[TBL] [Abstract][Full Text] [Related]
27. Coping with TB immune reconstitution inflammatory syndrome.
Worodria W; Conesa-Botella A; Kisembo H; McAdam KP; Colebunders R
Expert Rev Respir Med; 2009 Apr; 3(2):147-52. PubMed ID: 20477308
[TBL] [Abstract][Full Text] [Related]
28. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
[TBL] [Abstract][Full Text] [Related]
29. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.
Bolhaar MG; Karstaedt AS
Clin Infect Dis; 2007 Jul; 45(2):254-60. PubMed ID: 17578788
[TBL] [Abstract][Full Text] [Related]
30. Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment.
Banda H; Kang'ombe C; Harries AD; Nyangulu DS; Whitty CJ; Wirima JJ; Salaniponi FM; Maher D; Nunn P
Int J Tuberc Lung Dis; 2000 Oct; 4(10):968-74. PubMed ID: 11055765
[TBL] [Abstract][Full Text] [Related]
31. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.
Moore D; Liechty C; Ekwaru P; Were W; Mwima G; Solberg P; Rutherford G; Mermin J
AIDS; 2007 Mar; 21(6):713-9. PubMed ID: 17413692
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
[TBL] [Abstract][Full Text] [Related]
33. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition.
Sharma SK; Dhooria S; Barwad P; Kadhiravan T; Ranjan S; Miglani S; Gupta D
Indian J Med Res; 2010 Jun; 131():804-8. PubMed ID: 20571170
[TBL] [Abstract][Full Text] [Related]
34. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy.
Walters E; Cotton MF; Rabie H; Schaaf HS; Walters LO; Marais BJ
BMC Pediatr; 2008 Jan; 8():1. PubMed ID: 18186944
[TBL] [Abstract][Full Text] [Related]
35. Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya.
Huerga H; Spillane H; Guerrero W; Odongo A; Varaine F
Int J Tuberc Lung Dis; 2010 May; 14(5):611-5. PubMed ID: 20392355
[TBL] [Abstract][Full Text] [Related]
36. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus.
López-Gatell H; Cole SR; Hessol NA; French AL; Greenblatt RM; Landesman S; Preston-Martin S; Anastos K
Am J Epidemiol; 2007 May; 165(10):1134-42. PubMed ID: 17339383
[TBL] [Abstract][Full Text] [Related]
37. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary study of the Th17/Treg immunoregulation in patients coinfected with TB and HIV before and after HAART].
Liu YX; Yang GL; Zhou Y; Zhang HM; Zhang JY; Wang SY; Liu Y; Liu ST; Zhang LK; Wang H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):348-50. PubMed ID: 22338221
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS.
Williams BG; Dye C
Science; 2003 Sep; 301(5639):1535-7. PubMed ID: 12920302
[TBL] [Abstract][Full Text] [Related]
40. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
Bwire R; Nagelkerke NJ; Borgdorff MW
Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
